Design and Synthesis of Inhaled p38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease
Authors:
- 28 October 2011
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 54 (22) , 7797-7814
Abstract
This paper describes the identification and optimization of a novel series of DFG-out binding p38 inhibitors as inhaled agents for the treatment of chronic obstructive pulmonary disease. Structure based drug design and “inhalation by design” principles have been applied to the optimization of the lead series exemplied by compound 1a. Analogues have been designed to be potent and selective for p38, with an emphasis on slow enzyme dissociation kinetics to deliver prolonged lung p38 inhibition. Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimize systemic exposure and reduce systemically driven adverse events. High CYP mediated clearance and glucuronidation were targeted to achieve high intrinsic clearance coupled with multiple routes of clearance to minimize drug–drug interactions. Furthermore, pharmaceutical properties such as stability, crystallinity, and solubility were considered to ensure compatibility with a dry powder inhaler. 1ab (PF-03715455) was subsequently identified as a clinical candidate from this series with efficacy and safety profiles confirming its potential as an inhaled agent for the treatment of COPD.Keywords
This publication has 21 references indexed in Scilit:
- Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory DisordersJournal of Medicinal Chemistry, 2009
- Glucocorticoid resistance in inflammatory diseasesThe Lancet, 2009
- p38α-Selective Mitogen-Activated Protein Kinase Inhibitor SD-282 Reduces Inflammation in a Subchronic Model of Tobacco Smoke-Induced Airway InflammationThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Increased activation of p38 MAPK in COPDEuropean Respiratory Journal, 2007
- Global burden of COPD: risk factors, prevalence, and future trendsThe Lancet, 2007
- Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled TrialClinical Gastroenterology and Hepatology, 2006
- Inhaled p38α Mitogen-activated Protein Kinase Antisense Oligonucleotide Attenuates Asthma in MiceAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Pharmacological treatment of established rheumatoid arthritisBest Practice & Research Clinical Rheumatology, 2003
- Food manufacturing and the allergic consumer: Accidents waiting to happenJournal of Allergy and Clinical Immunology, 2002
- Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseasesCurrent Opinion in Immunology, 1991